88052
document
Effects of ORG-2766 on brain event-related potentials of autistic children . A double-blind , placebo-controlled study examined the effects of 6 weeks of treatment with the adrenocorticotropin4-9 analogue ORG-2766 ( 40 mg/day ) on brain event-related potentials ( ERPs ) of autistic children . In visual and auditory oddball paradigms ( with task and nontask conditions ) , standard ( 80 % ) , target ( 10 % ) , and unexpected novel stimuli ( 10 % ) were presented . ORG-2766 ( a ) increased the occipital P3 component of the ERP to visual targets , ( b ) decreased the occipital P3 component of the ERP to auditory targets , ( c ) did not affect visual and auditory parietal target P3 components , and ( d ) also did not affect the A/Pcz/300 to auditory novel stimuli . In addition , ORG-2766 treatment increased the N1 component of the ERP to task-irrelevant auditory stimuli .
88053
Intervention_Pharmacological
ORG-2766
88054
Intervention_Pharmacological
adrenocorticotropin4-9 analogue ORG-2766
88055
Outcome_Physical
increased the occipital P3 component of the ERP to visual targets
88056
Outcome_Physical
( b ) decreased the occipital P3 component of the ERP to auditory targets
88057
Outcome_Physical
( c ) did not affect visual and auditory parietal target P3 components
88058
Outcome_Physical
increased the N1 component of the ERP to task-irrelevant auditory stimuli
88059
Participant_Condition
autistic children .